Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients

  • STATUS
    Recruiting
  • End date
    Sep 1, 2025
  • participants needed
    560
  • sponsor
    AstraZeneca
Updated on 17 April 2021
fever
lymphoid leukemia
anemia
chronic lymphocytic leukemia
tyrosine
fatigue
thrombocytopenia
TP53
lymphadenopathy
night sweats
lymphocytosis
chronic lymphocytic leukemia refractory
recurrent chronic lymphocytic leukemia
acalabrutinib

Summary

This is a global, Phase 3b, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg bid in approximately 600 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 cohorts: treatment-naive (TN), relapsed/refractory (R/R), and prior Bruton tyrosine kinase inhibitor (BTKi) therapy. Participants will remain on study treatment until completion of 48 cycles (28 days per cycle), disease progression, toxicity requiring discontinuation, withdrawal of consent, lost to follow-up, death, or study termination by the sponsor whichever occurs first. The duration of the study will be approximately 72 months from the first participant enrolled. This duration includes an estimated 24-month recruitment time and an assumed 48 cycles of study treatment (28 days per cycle); additional study time will be accrued during the follow-up period for those participants remaining on study treatment after completion of 48 cycles (the amount of time will vary by participant).

Description

This is a Phase 3b, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg bid in approximately 600 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 cohorts: treatment-naive (TN) (minimum of 300 participants), relapsed/refractory (R/R) (approximately 200 participants), and prior bruton tyrosine kinase inhibitor (BTKi) therapy (up to 70 to 100 participants). Assessment of response and progression will be conducted by the investigator in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2018 criteria. Overall response assessments will be based on evaluation of physical examinations, recording of symptoms, radiologic evaluations, and hematologic evaluations. Study treatment (acalabrutinib 100 mg bid) will be administered until disease progression, unacceptable toxicity, 48 cycles of study treatment, withdrawal of consent, loss to follow-up, death, or study termination by the sponsor, whichever comes first (each cycle is 28 days). In-clinic visits will occur every cycle for the first 6 cycles, and then every 3 cycles for the next 6 cycles. After 12 cycles "in-clinic visits" will occur every 6 cycles. Safety follow up visits will occur approximately 30 days from the last dose of study treatment. If a participant continues to derive benefit from treatment at the end of 48 cycles, they will continue to be provided with study treatment. This may include, but not be limited to, transition to a long-term extension trial, continuous supply in this trial (for eg in countries where regulatory approval is not obtained, or drug is not reimbursed) or switching to commercial drug as permitted by local regulations. Participants who remain in the trial after the completion of 48 cycles will be followed for disease progression, description of all subsequently administered anticancer therapies, and IWCLL indication for initiation of subsequent anticancer therapies q24w via standard practice until transition to regulatory approved off-study acalabrutinib, withdrawal of consent, lost to follow-up, death, or study termination by the sponsor. Participants who switch to off-study acalabrutinib will be considered as having completed the study and therefore will not have any additional study assessments, including the disease follow-up period. The duration of the study will be approximately 72 months from the first participant enrolled. This duration includes an estimated 24-month recruitment time and an assumed 48 cycles of study treatment (28 days per cycle).

Details
Condition Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Chronic, leukemia chronic lymphocytic, chronic lymphocytic leukemia (cll), small lymphocytic lymphoma
Treatment acalabrutinib
Clinical Study IdentifierNCT04008706
SponsorAstraZeneca
Last Modified on17 April 2021

Eligibility

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note